0001493152-23-013724.txt : 20230427 0001493152-23-013724.hdr.sgml : 20230427 20230426183148 ACCESSION NUMBER: 0001493152-23-013724 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230427 DATE AS OF CHANGE: 20230426 EFFECTIVENESS DATE: 20230427 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kairos Pharma, LTD. CENTRAL INDEX KEY: 0001962011 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462993314 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-480119 FILM NUMBER: 23851219 BUSINESS ADDRESS: STREET 1: 2355 WESTWOOD BLVD. #139 CITY: LOS ANGELES STATE: CA ZIP: 90064 BUSINESS PHONE: 818-404-5541 MAIL ADDRESS: STREET 1: 2355 WESTWOOD BLVD. #139 CITY: LOS ANGELES STATE: CA ZIP: 90064 D 1 primary_doc.xml X0708 D LIVE 0001962011 Kairos Pharma, LTD. 2355 WESTWOOD BLVD. #139 LOS ANGELES CA CALIFORNIA 90064 (310) 948-2356 DELAWARE NanoGB13, Inc. None Corporation true John Yu c/o Kairos Pharma, Ltd. 2355 Westwood Blvd. #139 Los Angeles CA CALIFORNIA 90064 Executive Officer Director Chief Executive Officer and Chairman Neil Bhowmick c/o Kairos Pharma, Ltd. 2355 Westwood Blvd. #139 Los Angeles CA CALIFORNIA 90064 Executive Officer Chief Scientific Officer Ramachandran Murali c/o Kairos Pharma, Ltd. 2355 Westwood Blvd. #139 Los Angeles CA CALIFORNIA 90064 Executive Officer Vice President of Research and Development Doug Samuelson c/o Kairos Pharma, Ltd. 2355 Westwood Blvd. #139 Los Angeles CA CALIFORNIA 90064 Executive Officer Chief Financial Officer Hyun Bae c/o Kairos Pharma, Ltd. 2355 Westwood Blvd. #139 Los Angeles CA CALIFORNIA 90064 Director Independent director Pharmaceuticals Decline to Disclose 06b false 2022-06-30 false true true false 25000 Boustead Securities, LLC 141391 None None 6 VENTURE IRVINE CA CALIFORNIA 92618 CA CALIFORNIA MI MICHIGAN NV NEVADA PR PUERTO RICO false 3000000 675000 2325000 In June and September 2022, the issuer sold a total of $675,000 in convertible notes to certain accredited investors, which notes are convertible into shares of common stock. false 9 106208 0 0 true Boustead Securities, LLC acted as placement agent and received 7.0% cash and warrants to purchase shares of common stock equal to 7.0% of the number of conversion shares issuable in the offering. false Kairos Pharma, LTD. /s/ John S. Yu John S. Yu Chief Executive Officer 2023-04-26